ETFs & Funds
Home›ETFs & Funds›Fund Industry›Insmed shares slide as investors weigh early Brinsupri…
Insmed shares slide as investors weigh early Brinsupri launch dynamics
In the quarter, the fund said Insmed detracted even as it reported generally better-than-expected results, with investor focus on early patient additions for Brinsupri.
Insmed Incorporated shares came under pressure as investors reassessed early launch dynamics for its Brinsupri treatment, according to a Q2 2026 investor letter tied to the Alger Mid Cap Focus Fund published by Yahoo Finance. The letter highlighted that Insmed is a commercial-stage biopharmaceutical company focused on therapies for serious and rare diseases, including respiratory and inflammatory and pulmonary conditions. It noted that the company has an approved portfolio that includes Brinsupri and Arikayce. Insmed was cited as a contributor to fund performance headwinds during the quarter, with the fund stating the stock detracted despite headline results generally better than expected. The main concern, per the letter, was early launch dynamics, particularly patient additions for Brinsupri. As background on market context in the quarter, Yahoo Finance said the S&P 500 Index returned 15.2% in Q2 2026, supported by a ceasefire between the United States and Iran and accelerated investment in artificial intelligence, while Energy and Utilities lagged due to falling oil and gas prices. The letter also described that the fund benefited from strength in Information Technology and Health Care during the quarter.
Latest closeS&P 500 7,533.77 ▼0.5%